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Whole-body periodic acceleration (WBPA) has been developed as a passive exercise device 
capable of improving endothelial function by applying pulsatile shear stress to vascular 
endothelium.  We hypothesized that treatment with WBPA improves exercise capacity, 
myocardial ischemia and left ventricular (LV) function as a result of increased coronary and 
peripheral vasodilatory reserves in angina patients.  Twenty-six angina patients who were not 
indicated for percutaneous coronary intervention and/or coronary artery bypass grafting were 
randomly assigned to remain sedentary (Sedentary group) or to undergo 20 sessions of WBPA 
with the motion platform for 4 weeks (WBPA group) in addition to conventional medical 
treatment.  WBPA was applied at 2 to 3 Hz and approximately ±2.2 m/sec
2
 for 45 min.  We 
repeated the symptom-limited treadmill exercise test and adenosine sestamibi myocardial 
scintigraphy.  In the WBPA group, the exercise time until 0.1 mV ST depression increased by 
53% (p<.01), and the double product at 0.1 mV ST depression by 23% (p<.001).  The 
severity score of myocardial scintigraphy during adenosine infusion decreased from 20±10 to 
14±8 (p<.001), and resting severity score also decreased from 13±10 to 8±10 (p<.01).  In 
resting scintigraphic images, LV end-diastolic volume index decreased by 18% (p<.01) with 
an augmentation of LV ejection fraction from 50±16% to 55±16% (p<.01).  In contrast, all 
aforementioned parameters remained unchanged in the sedentary group.  In conclusion, 
treatment with WBPA for angina patients ameliorates exercise capacity, myocardial ischemia 
and LV function. 
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Introduction 
Recently, Sackner et al.
1, 2
 invented whole-body periodic acceleration (WBPA), a new 
therapeutic device capable of improving endothelial function by applying pulsatile shear 
stress to vascular endothelium, presumably owing to the production and release of vasoactive 
substances such as nitric oxide.
3, 4
  Heparin possesses several functions besides an 
anticoagulant effect.  Heparin potentiates and accelerates coronary collateral growth 
resulting from interaction with angiogenic growth factors.
5
  Heparin also increases the 
bioavailability of nitric oxide by liberating vessel-immobilized myeloperoxidase.
6
  We 
designed the present study to test the impact of repeated WBPA therapy with heparin 
pretreatment on exercise capacity, myocardial ischemia, and left ventricular (LV) function in 
patients with angina pectoris and mild LV dysfunction. 
Methods 
We investigated 26 patients (19 men, 7 women) aged between 45 and 86 years (mean 68 ± 
10 years) with chronic effort angina and mild LV dysfunction with an ejection fraction (EF) 
below 55% (mean 51 ± 10 %).  All had angiographically proven significant coronary 
narrowing (≥ 75%) involving one or more major coronary arteries and developed ≥ 0.1 mV 
ST-segment depression during treadmill exercise testing.  None had acute exacerbation of 
symptoms in the preceding 6 months.  Patients were randomized to remain sedentary 
(Sedentary group, n = 13) or to undergo heparin WBPA therapy (WBPA group, n = 13).  All 
patients underwent conventional medical therapy throughout the study.  WBPA was applied 
-4- 
with a gurney-like motion platform device (Acceleration Therapeutics AT101; Non-Invasive 
Monitoring Systems; North Bay Village, FL) at a frequency of 2-3 Hz and approximately ± 
2.2 m/sec
2
 for 45 minutes.
1, 2
  A single intravenous dose of heparin (5,000 IU) was given 10 
to 20 min before each WBPA.  The procedure was repeated 20 times over 4 weeks.  
Primary endpoints of the present study were improvements in exercise capacity, myocardial 
ischemia and LV size and function.  The study protocol complied with the Declaration of 
Helsinki was approved by the ethics committee of Kitano Hospital, and all patients gave 
written informed consent for the study. 
Before performing the baseline exercise test, all patients carried out preliminary treadmill 
exercise several times to habituate themselves to the test.  All anti-angina medications were 
withdrawn at least 2 days before the study.  Sublingual nitroglycerin was allowed for angina 
symptom relief.  Symptom-limited graded treadmill exercise testing was performed with a 
standard Bruce protocol in a fasting state, and a post-treatment treadmill exercise test was 
repeated at the same time of day as the baseline test.
7
  A 12-lead electrocardiogram was 
recorded at rest and 1-minute intervals until the onset of limiting chest pain, leg fatigue or ≥ 
0.2 mV ST-segment depression.  Blood pressure was measured with a sphygmomanometer 
during each minute of exercise and recovery.  Time to 0.1 mV ST-segment depression was 
defined as the elapsed time from initiation of exercise to the occurrence of horizontal or 
down-sloping 0.1-mV ST-segment depression measured at 80 ms after the J point.  In this 
study, the heart rate and systolic blood pressure at the onset of 0.1 mV ST-segment depression 
-5- 
were measured to determine the ischemic threshold.  All exercise tests and ST-segment 
evaluations were performed by investigators blinded to the results of coronary angiograms 
and treatment status. 
Adenosine myocardial perfusion single photon emission computed tomography was 
performed as described previously.
8
  Adenosine was infused at 140 g/kg/min for 5 minutes.  
At the end of the second minute, Tc-99m sestamibi (25-40 mCi) was injected, and myocardial 
perfusion single photon emission computed tomography acquisition was started 
approximately 60 minutes later.  We used software developed at Cedars-Sinai Medical 
Center, called quantitative gated single photon emission computed tomography,
9, 10
 capable of 
providing simultaneous assessment of LV perfusion, global function (either systolic and 
diastolic) and regional wall thickening and motion.  Visual interpretation of myocardial 
perfusion single photon emission computed tomography images was based on short-axis and 
vertical long-axis tomograms divided into 17 segments.
11
  Each segment was scored by 2 
expert observers blinded to the treatment group using a 5-point scoring system (0, normal; 1, 
mildly abnormal; 2, moderately abnormal; 3, severely abnormal; and 4, absence of segmental 
uptake).  Subsequently, summed stress and rest scores were calculated by summing of 
respective segmental scores.
12
  The maximal score was therefore 68 (17 segments × score 4).  
When visual scoring was different between the 2 observers, they assessed again the 
myocardial perfusion images and reached a consensus.  Quantitative measurements of LVEF 
using gated perfusion single photon emission computed tomography were usually 
-6- 
volume-based rather than count-based methods.  In particular, the time-volume curve 
derived from 16-frame gating allowed the end-diastolic volume (EDV) and end-systolic 
volume (ESV) of the LV cavity to be identified, from which the LVEF was calculated as 
follows: %LVEF = (LVEDV- LVESV)/ LVEDV × 100. 
Data are expressed as the mean ± SD.  A two-way analysis of variance using 
Bonferroni’s method was carried out to investigate differences in the treadmill exercise test 
and adenosine myocardial perfusion scintigraphy.  Significance was designated at the 
probability value of p < 0.05. 
Results 
All 26 patients completed the protocol without any complications or adverse effects.  No 
hemorrhagic tendency was noted in any of the patients treated with heparin.  Weekly 
urinalysis and stool occult blood tests revealed negative results. 
The baseline characteristics of the study patients are listed in Table 1.  There were no 
significant differences in age, gender, risk factors and disease complications between the 2 
groups.  The distribution of the ischemia-related artery was similar in the 2 groups.  The 
number of involved vessels was also comparable between the 2 groups.  Similarly, there 
were no significant differences in medication between the 2 groups. 
Exercise time and hemodynamic parameters at rest and at 0.1 mV ST depression during 
the treadmill exercise test are summarized in Table 2.  There were no significant differences 
in resting hemodynamic parameters at baseline and after treatment between the 2 groups.  In 
-7- 
the sedentary group, the exercise time to 0.1 mV ST depression remained unchanged before 
and after the conventional treatment.  In contrast, in the WBPA group, WBPA with heparin 
pretreatment significantly increased the exercise time to 0.1 mV ST depression.  In the 
sedentary group, the double product at 0.1 mV ST depression remained unchanged before and 
after conventional treatment.  In contrast, in the WBPA group it was significantly (p < .001) 
increased. 
Figure 1 shows 2 representative cases in each group.  In a patient of the sedentary group, 
in the LV short-axial and horizontal long-axial view, posterolateral hypoperfusion or defect 
and LV size remained unchanged as determined by both stress and at rest imaging after 
conventional treatment (Figure 1; left panels).  In a patient of the WBPA group, in the LV 
short-axial and horizontal long-axial view, posterolateral hypoperfusion or defect clearly 
improved as determined by both stress and at rest imaging after heparin WBPA treatment.  In 
addition, LV size remarkably decreased as determined by both stress and at rest imaging after 
treatment (Figure 1; right panels).  At baseline, the summed stress and rest scores of 
adenosine myocardial perfusion scintigrams were comparable between the 2 groups.  The 
summed stress and rest scores remained unchanged in the sedentary group.  In contrast, in 
the WBPA group after treatment with heparin WBPA therapy, the summed stress and rest 
scores significantly decreased (Figure 2).  Changes in global LV parameters (EDVI, ESVI, 
EF) are summarized in Figure 3.  At baseline, the LVEDVI, LVESVI and LVEF were similar 
between the 2 groups.  In the sedentary group, all global LV parameters remained unchanged 
-8- 
after conventional treatment (Figure 3; left panels).  In the WBPA group, we found 
significantly smaller LVEDVI and LVESVI after treatment.  In addition, LVEF significantly 
increased (Figure 3; right panels). 
Discussion 
The present study has demonstrated that repeated WBPA with a motion platform 
combined with heparin pretreatment attenuates stress-induced myocardial ischemia and 
improves resting LV systolic function with a reversal of LV remodeling in patients with 
angina pectoris and mild LV dysfunction.  This is the first clinical report to show that 
heparin WBPA treatment is effective in alleviating exercise-induced myocardial ischemia and 
improving cardiac morphology and performance in patients with advanced coronary artery 
disease. 
In our treated patients, the rate-pressure product at 0.1 mV ST depression increased by 
23% with heparin WBPA treatment.  This implies an increase in blood flow supply to the 
potentially ischemic area,
7, 13, 14
 which was confirmed by myocardial perfusion scintigraphy 
during adenosine infusion.  These findings suggest that coronary flow reserve to the 
potentially ischemic area was augmented by the treatment.  There are 3 possible mechanisms 
of the increased flow reserve.  First, increased pulsatile shear stress resulting from WBPA 
treatment activates production and release of angiogenic growth factors and leads to 
arteriogenesis.
5, 15
  Second, WBPA increases the release from the endothelium of 




These substances may contribute to arteriogenesis and/or angiogengesis.
16, 17
  Third, 
endothelial dysfunction plays an important role in the pathogenesis of decreased coronary 
flow reserve.
18
  Improvement of coronary endothelial function, which is speculated from the 
improved endothelial function in the peripheral circulation with WBPA,
19, 20
 enhances 
coronary flow reserve in the area supplied with severely narrowed coronary artery and/or 
collateral vessels.
21
  Indeed, we have recently documented that WBPA improves coronary 
flow reserve in healthy subjects and patients with coronary artery disease.
22
 
In our treated patients, the rate-pressure product at the same exercise time was 
significantly decreased (data not shown).  This implies that heparin WBPA treatment may 
provide a peripheral effect via nitric oxide production, which is the case in exercise 
rehabilitation in patients with coronary artery disease.
23
  Thus, the increased exercise 
capacity after the treatment may, at least in part, be attributed to a training effect.  
Alternatively, cardiac protection may have been achieved as a result of WBPA.  WBPA has 
also been shown to upregulate eNOS in the heart.
4
  Cardiac preconditioning is a polygenic 
process resulting in de novo synthesis of cardioprotective proteins.
24
  The 
preconditioning-mimetic actions of nitroglycerin have been demonstrated in an elegant study 
by Leesar et al..
25
  The preconditioning effect of WBPA was also documented in an animal 
study.
26
  Thus, cardiac preconditioning potentially suppresses myocardial oxygen 
consumption during exercise with a resultant improvement of exercise capacity. 
In our patients with heparin WBPA treatment, scintigraphically evaluated resting LV 
-10- 
function significantly improved.  It is well known that “hibernating” myocardium recovers 
contractile force soon after revascularization procedures such as percutaneous coronary 
intervention and coronary artery bypass grafting.
27
  A reduction in “hibernating” 
myocardium in our treated patients was shown by the fact that the defect score of myocardial 
perfusion scintigraphy at rest was significantly decreased after treatment.  Another 
explanation of LV functional recovery is an unloading effect resulting from decreased 
peripheral vascular resistance as a result of improved endothelial function in peripheral 
circulation. 
Heparin was administered as a pretreatment of WBPA for two reasons.  First, we have 
previously developed heparin exercise treatment for patients with chronic effort angina.
13
  
The efficacy of heparin on coronary collateral growth has been confirmed by several clinical 
studies.
5
  It is important that heparin does not initiate but rather potentiates arteriogenesis in 
combination with exercise.  Therefore, the presence of angiogenic growth factors is 
indispensable for the effect of heparin.  Indeed, in angina patients treated with heparin alone 
the total treadmill exercise time remained unchanged (414 ± 126 versus 408 ± 66 (SD) sec).
28
  
This is also a reason why heparin was not administrated in the control group.  Second, 
heparin has been reported to increase the bioavailability of nitric oxide by liberating 
vessel-immobilized myeloperoxidase.
6
  Thus, we expected that the beneficial effect of 
WBPA on endothelial function would be potentiated by heparin pretreatment. 
It is tempting to compare the effect of heparin WBPA treatment with other therapeutic 
-11- 
modalities.  In this study, the treadmill exercise time to 0.1 mV ST depression was 
significantly increased from 261 ± 123 to 400 ± 164 (SD) sec, which was comparable with the 
effect of heparin exercise treatment.
13
  In angina patients enrolled in the multicenter study of 
enhanced external counterpulsation (MUST-EECP), the exercise time to 0.1 mV ST 
depression was increased significantly from 337 ± 18 to 379 ± 18 (SEM) sec.
29
  Six week 
treatment (diltiazem, 360 mg/day) for patients with effort angina significantly increased the 
exercise time to 0.1 mV ST depression from 198 ± 24 to 324 ± 36 (SEM) sec.
30
  Although 
direct comparison among these studies may be limited because of the differences in the 
patient population, medications and protocols in the treadmill exercise test, heparin WBPA 
treatment appears to be a promising therapeutic modality. 
One limitation of the present study is the lack of a group of patients with WBPA without 
heparin.  Since the present study was designed to document the efficacy of a new therapeutic 
modality for angina patients who are not indicated for percutaneous coronary intervention 
and/or coronary artery bypass grafting, we expected maximal effects of the treatment by 
combining WBPA with heparin.  In future studies, it should be examined whether WBPA 
alone is also efficacious for relieving effort angina and improving LV dysfunction.  Further 
investigations are needed to elucidate more precise mechanisms underlying the efficacy of the 
treatment.  Prospective, randomized trials comprised of a large number of patients are also 
needed to confirm the effectiveness of this treatment. 
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Figure legends 
Figure 1.  Myocardial scintigrams in representative cases.  Changes in myocardial 
perfusion scintigrams during adenosine infusion in representative cases (A), and changes in 
myocardial perfusion scintigrams at rest in the same representative cases as in A (B).  Upper 
panels, short axial images; lower panels, horizontal long-axial images. 
 
Figure 2.  Summary data on myocardial scintigrams.  Changes in summed stress score in 
myocardial scintigrams during adenosine infusion (A), and changes in summed rest score in 
myocardial scintigrams at rest (B).  Bars indicate the mean ± SD. 
 
Figure 3.  Summary data on global LV function.  Changes in the LVEDVI index (A), 
LVESVI (B) and LVEF (C).  Bars indicate the mean ± SD.  LV = left ventricular; LVEDVI 
= left ventricular end-diastolic volume index; LVEF = left ventricular ejection fraction; 
LVESVI = left ventricular end-systolic volume index. 
Table 1  Baseline patient characteristics 
Variable 
Sedentary group 
(n = 13) 
WBPA group 
(n = 13) 
Age (years) 66 ± 10 69 ± 10 
Men/women 10/3 9/4 
Hypertension 10 (77%) 10 (77%) 
Diabetes mellitus 7 (54%) 7 (54%) 
Hypercholesterolemia 10 (77%) 8 (62%) 
Cigarette smoker 6 (46%) 4 (31%) 
Body mass index (kg/m
2
) 22.6 ± 3.4 23.5 ± 3.1 
Renal failure 5 (38%) 5 (38%) 
Number of involved coronary arteries 2.3 ± 0.8 2.5 ± 0.7 
Ischemia-related coronary artery 
Right 








Healed myocardial infarction 5 (38%) 7 (54%) 
Prior percutaneous coronary intervention 6 (46%) 6 (46%) 
Prior coronary artery bypass grafting 5 (38%) 5 (38%) 
Arteriosclerosis obliterans 1 (8%) 4 (31%) 
Prior cerebral infarction 3 (23%) 0 (0%) 
Canadian Cardiovascular Society of classification of effort angina 
Class II 11 (85%) 10 (77%) 
Class III 2 (15%) 3 (23%) 
Class IV 0 (0%) 0 (0%) 
Medication 
Aspirin 13 (100%) 13 (100%) 
Angiotensin converting enzyme inhibitor 3 (23%) 1 (8%) 
Angiotensin II receptor blocker 6 (46%) 7 (54%) 
Beta-blocker 8 (62%) 10 (77%) 
Calcium-blocker 5 (38%) 6 (46%) 
Statin 10 (77%) 6 (46%) 
Pioglitazone 0 (0%) 1 (8%) 
Diuretic 5 (38%) 6 (46%) 
 
Values are the mean ± SD. 
Sedentary group, patients with conventional medical therapy alone; WBPA group, patients with 
whole-body periodic acceleration therapy with heparin pretreatment plus conventional medical 
therapy. 
Table 1
 Table 2  Changes in treadmill exercise time and hemodynamic parameters 
at rest and 0.1 mV ST depression 
Variable 







Exercise time (sec) 269 ± 186 244 ± 159  261 ± 123 400 ± 164*† 
Heart rate (beats/min) 
resting 70 ± 8 69 ± 9  68 ± 6 68 ± 8 
ischemia 111 ± 15 107 ± 17  112 ± 10 115 ± 9 
Systolic blood pressure (mmHg) 
resting 122 ± 12 125 ± 11  121 ± 12 119 ± 12 
ischemia 138 ± 19 134 ± 21  136 ± 24 163 ± 29*† 
Rate-pressure product × 10
−2
 (mmHg × beats/min) 
resting 86 ± 15 86 ± 14  82 ± 10 81 ± 10 
ischemia 154 ± 37 145 ± 41  154 ± 35 189 ± 39*† 
 
Data are presented as the mean value ± SD. 
Sedentary group, patients with conventional medical therapy alone; WBPA group, patients 
with whole-body periodic acceleration therapy with heparin pretreatment plus conventional 
medical therapy.  *p < 0.01 vs. baseline values; †p < 0.01 vs. Sedentary group. 
WBPA = whole-body periodic acceleration. 
Table 2
Figure 1
A    During Adenosine Infusion
B    At rest
Sedentary group WBPA group
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Figure 2
A  Summed Stress Score
B  Summed Rest Score
p=ns p=0.0004
Sedentary group WBPA group
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Figure 3A  LVEDVI
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